07:00 , May 23, 2011 |  BC Week In Review  |  Company News

Algen Biopharmaceuticals, BioLineRx deal

BioLineRx acquired exclusive rights to cancer candidate BL-7030 from Algen. The double-stranded RNA vector targeting EGFR is in preclinical testing. Algen has rights from the Hebrew University of Jerusalem (Jerusalem, Israel). Further terms...
07:00 , Aug 26, 2002 |  BioCentury  |  Tools & Techniques

RNAs long on toxicity

Antisense cancer therapeutics typically aim to down-regulate oncogenic proteins. But researchers at the Hebrew University in Jerusalem last week reported on a different strategy, using antisense RNA to increase the activity of PKR kinase, ultimately...